Journal of Molecular and Cellular Cardiology
Volume 49, Issue 3 , Pages 469-481, September 2010

Therapy with granulocyte colony-stimulating factor in the chronic stage, but not in the acute stage, improves experimental autoimmune myocarditis in rats via nitric oxide

  • Kana Shimada

      Affiliations

    • Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
  • ,
  • Taka-aki Okabe

      Affiliations

    • Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
  • ,
  • Yu Mikami

      Affiliations

    • Department of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan
  • ,
  • Miki Hattori

      Affiliations

    • Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
  • ,
  • Masatoshi Fujita

      Affiliations

    • Department of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan
  • ,
  • Chiharu Kishimoto

      Affiliations

    • Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
    • Corresponding Author InformationCorresponding author. Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, 54 Kawaracho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan. Tel.: +81 075 751 3197; fax: +81 075 751 4281.

Received 30 January 2010; accepted 4 February 2010. published online 18 February 2010.

Abstract 

We systematically investigated serial efficacy of granulocyte colony-stimulating factor (G-CSF) therapy upon experimental autoimmune myocarditis (EAM) in rats treated with and without the inhibition of nitric oxide (NO) with the analyses of tissue regeneration. G-CSF could mobilize multipotent progenitor cells of bone marrow into the peripheral blood and may improve ventricular function. A rat model of porcine myosin-induced EAM was used. After the immunization of myosin, G-CSF (10μg/kg/day) or saline was injected intraperitoneally on days 0–21 in experiment 1 and on days 21–42 in experiment 2. Additional myosin-immunized rats were orally given 25mg/kg/day of NG-nitro-l-arginine methylester (l-NAME), an inhibitor of nitric oxide synthase (NOS), in each experiment (each group; n=8–21). Serum cytokines and peripheral blood cell counts were measured in each group. In experiment 1, G-CSF treatment aggravated cardiac pathology associated with increased macrophage inflammatory protein-2 (MIP-2) and interleukin-6 (IL-6) levels and enhanced superoxide production. In experiment 2, G-CSF treatment reduced the severity of myocarditis with increased capillary density and improved left ventricular ejection fraction. In the rats with EAM treated with G-CSF associated with oral l-NAME treatment in experiment 2, the severity of myocarditis was not reduced. Myocardial c-kit+ cells were demonstrated only in G-CSF-treated group in experiment 2 but not in other groups. G-CSF has differential effects on EAM in rats associated with the modulation of cytokine network. The overwhelming superoxide production by G-CSF administration in the acute stage may worsen the disease. G-CSF therapy improved cardiac function via NO system in a rat model of myocarditis in the chronic stage, but not in the acute stage, possibly through the myocardial regeneration and acceleration of healing process.

Keywords: Autoimmune myocarditis, Granulocyte colony-stimulating factor (G-CSF), Tissue regeneration, Nitric oxide (NO), Cardiac function, Cytokines

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0022-2828(10)00038-6

doi:10.1016/j.yjmcc.2010.02.003

Journal of Molecular and Cellular Cardiology
Volume 49, Issue 3 , Pages 469-481, September 2010